&NA; On March 28–29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice‐changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.

中文翻译：

---

恶性间皮瘤的当前和未来管理：来自美国国家癌症研究所胸部恶性肿瘤指导委员会、国际肺癌研究协会和间皮瘤应用研究基金会的共识报告

&NA; 2017 年 3 月 28-29 日，美国国家癌症研究所 (NCI) 胸部恶性肿瘤指导委员会、国际肺癌研究协会和间皮瘤应用研究基金会召集了 NCI-国际肺癌研究协会-间皮瘤应用研究基金会间皮瘤临床试验计划会议在马里兰州贝塞斯达举行。会议的目标是将主要院士、临床医生、科学家和美国食品和药物管理局聚集在一起，专注于为已诊断出恶性胸膜间皮瘤的患者开展临床试验。鉴于发现了影响恶性间皮瘤新药和免疫疗法临床开发的新癌症靶点，